Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

University of Calgary

$135,000.00

The gut microbiome controls chronic post-inflammatory pain via STING

FY 2023-24

Summary
Pain is the most common cause of disability and impaired quality of life in inflammatory bowel disease or IBD. The goal of therapy is to reduce the clinical symptoms (e.g. pain, diarrhea and bloating) by controlling gastrointestinal inflammation. However, despite successful treatment of active disease, the symptoms of abdominal pain (i.e. irritable bowel syndrome-like symptoms) are out of proportion with the observed degree of inflammation. In fact, patients suffering pain may have complete mucosal healing. Clinical pain management relies mainly on narcotics, yet the "opioid epidemic" demonstrates the need of safer pain treatments. We recently identified this molecule named stimulator of interferon genes: STING as a central regulator of the resolution of pain. STING can recognize specific microbial products to alert the host from infection or tissue damage. Interestingly, there is evidence that both animal models and some IBD patients in remission exhibit persistent changes in the gut microbiome. This suggests a potential link between microbiome and chronic visceral pain through the modulation of neuronal STING. My project will determine the biological processes by which the microbiome regulates inflammatory pain via STING. Harnessing the power of STING and its downstream effector Type I Interferon to prevent pain may provide a unique therapeutic arsenal for patients suffering of pain during the quiescent phase of the disease. My project will also indicate the importance of microbial complexity in the regulation of neural-specific IFN responses, thus addressing whether neonatal antibiotics, diet, and other microbiota-disrupting factors can contribute to the onset of persistent pain conditions in adulthood. My work will ultimately identify targets of the STING signaling pathway, including bacterial-derived products or prebiotics that could rapidly enter clinical practice.
Program
CIHR Fellowship
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
492476
Name
Defaye Manon E
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
The gut microbiome controls chronic post-inflammatory pain via STING
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Behavior; Inflammation; Interferons; Microbiome; Sting; Trp Channels; Viceral Pain
Abstract
Pain is the most common cause of disability and impaired quality of life in inflammatory bowel disease or IBD. The goal of therapy is to reduce the clinical symptoms (e.g. pain, diarrhea and bloating) by controlling gastrointestinal inflammation. However, despite successful treatment of active disease, the symptoms of abdominal pain (i.e. irritable bowel syndrome-like symptoms) are out of proportion with the observed degree of inflammation. In fact, patients suffering pain may have complete mucosal healing. Clinical pain management relies mainly on narcotics, yet the "opioid epidemic" demonstrates the need of safer pain treatments. We recently identified this molecule named stimulator of interferon genes: STING as a central regulator of the resolution of pain. STING can recognize specific microbial products to alert the host from infection or tissue damage. Interestingly, there is evidence that both animal models and some IBD patients in remission exhibit persistent changes in the gut microbiome. This suggests a potential link between microbiome and chronic visceral pain through the modulation of neuronal STING. My project will determine the biological processes by which the microbiome regulates inflammatory pain via STING. Harnessing the power of STING and its downstream effector Type I Interferon to prevent pain may provide a unique therapeutic arsenal for patients suffering of pain during the quiescent phase of the disease. My project will also indicate the importance of microbial complexity in the regulation of neural-specific IFN responses, thus addressing whether neonatal antibiotics, diet, and other microbiota-disrupting factors can contribute to the onset of persistent pain conditions in adulthood. My work will ultimately identify targets of the STING signaling pathway, including bacterial-derived products or prebiotics that could rapidly enter clinical practice.
Competitiondate
202310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Defaye, Manon E
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~
University of Calgary - $135,000 Grant (2023-24) | Canada Spends